Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.

Benoist Chibaudel,Christophe Tournigand,May Mabro,Mohammed Bennamoun,Pascal Artru,S. Nguyen,J-B Bachet,Nasredine Aissat,Hélène Blons,Pierre Laurent-Puig,A. de Gramont,T. Andre,Gercor

Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.

2011

Benoist Chibaudel
Christophe Tournigand
May Mabro
Mohammed Bennamoun
Pascal Artru
S. Nguyen
J-B Bachet
Nasredine Aissat
Hélène Blons
Pierre Laurent-Puig
A. de Gramont
T. Andre
Gercor

3573 Background: Panitumumab alone in third-line chemotherapy increased objective response rate (ORR) from 0 to 17% (95% CI 11%-25%) and prolonged progression-free survival (PFS) versus best suppor...

Keywords:

Colorectal cancer
KRAS
Wild type
Phases of clinical research
Panitumumab
Pathology
Cancer research
Chemotherapy
Oncology
Internal medicine
Medicine
Irinotecan
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations